Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

Augmenting Standard Rehabilitation With Blood Flow Restriction for Chronic Achilles Tendinopathy

NCT07699497 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-08-01
Last updated
2026-07-13

Condition(s) studied

Achilles Tendinopathy (AT)

Investigational drug(s) / intervention(s)

Standard-of-Care Rehabilitation Program for Chronic Insertional Achilles TendinopathyBlood Flow Restriction (BFR) Training Device

Standard-of-Care Rehabilitation Program for Chronic Insertional Achilles Tendinopathy: Participants complete a standardized outpatient rehabilitation program for chronic insertional Achilles tendinopathy. Standard care includes progressive tendon/calf loading using an eccentric-loading emphasis, education and symptom-guided activity modification, and a graded return-to-function progression. The program is delivered under physical therapy supervision using standard exercise tools, with progression based on participant tolerance and clinical response.

Blood Flow Restriction (BFR) Training Device: Blood flow restriction (BFR) is applied during low-load resistance exercise using Smart Tools Plus cuffs and limb sleeves. The sleeve is used to protect the skin/soft tissue beneath the cuff, and the cuff is placed around the proximal thigh (right and left as applicable). Individual limb occlusion pressure (LOP) is determined immediately prior to exercise; cuff pressure is set to 40%-80% of LOP and maintained during the entire exercise set. Participants are monitored during BFR application for adverse signs/symptoms (e.g., excessive pain, numbness/paresthesia, abnormal discoloration), and BFR is stopped if safety concerns arise.

Study summary

Chronic insertional Achilles tendinopathy is a common overuse condition that can be slow to improve with traditional loading-based rehab (e.g., eccentric loading, activity modification, graded return to function). Outcomes are often variable, and persistent symptoms can limit how much load patients can tolerate early in rehab.

This outpatient randomized controlled trial will compare standard-of-care rehabilitation alone versus standard-of-care rehabilitation plus blood flow restriction (BFR) training in adults with chronic insertional Achilles tendinopathy. BFR uses an external cuff to partially restrict blood flow during low-load resistance exercise, aiming to produce strength and hypertrophy adaptations with less mechanical stress than high-load training. Evidence supporting BFR's physiologic effects and safety in musculoskeletal rehab is summarized in clinical research literature.

Participants will be randomized (stratified by baseline activity level and symptom severity) to receive the same rehab program, with the experimental group performing strengthening with BFR using Smart Tools Plus cuffs applied at the proximal thigh and set to 40-80% limb occlusion pressure. The primary outcome will be the VISA-A score (a validated measure of Achilles tendinopathy severity), with secondary outcomes including pain ratings, functional performance tests (e.g., single-leg heel raise endurance, hopping/time-to fatigue), and calf strength via handheld dynamometry.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Age 18-65 years * Chronic insertional Achilles tendinopathy (symptoms \>3 months but \<3 years) * VISA-A score \<80 * Confirmed diagnosis via: * Palpation pain within 2 cm of calcaneal insertion * Positive single leg-hop test * Ultrasound or MRI evidence of structural tendon changes (hypoechoic areas, thickening, or Doppler flow) * No prior BFR training as part of rehab within the last 3 months Exclusion Criteria: * Inability to give informed consent * Uncontrolled blood pressure (\>160/100 mmHg) * Uncontrolled diabetes * Familial hypercholesterolemia * History of deep vein thrombosis * History of blood clots * Hypercoagulable states * Cancer * Active infection * History of sickle cell anemia * Peripheral vascular disease * Morbid obesity (BMI \>40) * End-stage renal disease requiring dialysis * Alcohol use disorder / alcohol abuse * Claustrophobia * Pregnant woman * Inability to follow study protocol (e.g., cannot attend visits or comprehend instructions) * Psychiatric illness preventing comprehension or interfering with follow up * Lymphadenectomy * Any clinical finding that places the patient at health risk, impacts the study, or affects completion * History of Achilles tendon rupture or surgery * Concurrent midportion Achilles tendinopathy or other ankle pathology (e.g., arthritis) * Recent treatments within the past 3 months: physiotherapy, local injections, shockwave therapy, orthotic use

Primary outcome measure(s)

  • VISA-A (Victorian Institute of Sport Assessment-Achilles) Score — Baseline (pre-intervention) and Week 8 (end of intervention period)
    Description: Patient-reported outcome assessing Achilles tendinopathy severity; total score ranges 0-100 with higher scores indicating fewer symptoms/better function. This tool is validated for Achilles tendinopathy and commonly used in research/clinical settings.

Trial sites (1)

FacilityCityRegionStatus
Faculty of Medicine, Assiut University Asyut Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07699497 on ClinicalTrials.gov ↗ ← All trials in Egypt